How Strensiq Could Boost Alexion’s Long-Term Growth
Strensiq revenue trends
In 2Q17, Alexion Pharmaceuticals’ (ALXN) Strensiq generated revenues of ~$83 million, which was ~84% higher YoY (year-over-year) and ~12% higher QoQ (quarter-over-quarter). In 1H17, Strensiq reported revenues of ~$157 million, compared with $78 million in 1H16.
Interested in ALXN? Don't miss the next report.
Receive e-mail alerts for new research on ALXN
Geographical revenue trends
In 1H17, in the US, Europe, Asia-Pacific, and the rest of the world, Strensiq reported revenues of ~$133 million, ~$14 million, ~$8 million, and ~$2 million, respectively, compared with ~$67 million, ~$4 million, ~$6 million, and ~$1 million, in 1H16.
In 2Q17, in the US, Europe, Asia-Pacific, and the rest of world, Strensiq reported revenues of ~$70 million, ~$8 million, ~$4 million, and ~$1 million, respectively.
Notably, the iShares Core S&P 500 ETF (IVV) has ~0.15% of its total portfolio holdings in ALNX.
The Strensiq (asfotase alfa) injection is used for the treatment of perinatal and infantile and juvenile-onset HPP (hypophosphatasia).
In July 2017, Alexion established a funding agreement with NICE (National Institute for Health and Care Excellence) and the NHS (National Health Service) in England to help pediatric-onset HPP patients in England access Strensiq therapy, regardless of age. The funding agreement is expected to strengthen the position of Strensiq in England, as Strensiq has continued to gain strength in the US, Germany, and Japan.